Twist Bioscience Corporation (TWST) financial statements (2022 and earlier)
Company profile
| Business Address |
681 GATEWAY BLVD. SOUTH SAN FRANCISCO, CA 94080 |
| State of Incorp. | DE |
| Fiscal Year End | September 30 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2021 Q1 | 9/30/2021 Q4 | 6/30/2021 Q3 | 3/31/2021 Q2 | 12/31/2020 Q1 | 9/30/2020 Q4 | 6/30/2020 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 302 | 478 | 519 | 556 | 587 | 290 | 312 | ||
| Cash and cash equivalents | 192 | 466 | 475 | 399 | 349 | 94 | 208 | ||
| Short-term investments | 110 | 12 | 44 | 156 | 238 | 196 | 104 | ||
| Restricted cash and investments | 0 | ||||||||
| Receivables | 33 | 29 | 28 | 27 | 25 | 26 | 13 | ||
| Inventory, net of allowances, customer advances and progress billings | 40 | 32 | 21 | 16 | 13 | 12 | 13 | ||
| Inventory | 40 | 32 | 21 | 16 | 13 | 12 | 13 | ||
| Contract with customer, asset | 1 | ||||||||
| Other undisclosed current assets | 10 | 8 | 8 | 8 | 8 | 6 | 6 | ||
| Total current assets: | 385 | 546 | 577 | 608 | 634 | 335 | 345 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 72 | 62 | 63 | 31 | 32 | 34 | 35 | ||
| Property, plant and equipment | 65 | 44 | 38 | 32 | 27 | 25 | 24 | ||
| Long-term investments and receivables | 107 | ||||||||
| Long-term investments | 107 | ||||||||
| Intangible assets, net (including goodwill) | 148 | 41 | 41 | 1 | 1 | 1 | 1 | ||
| Goodwill | 84 | 22 | 23 | 1 | 1 | 1 | 1 | ||
| Intangible assets, net (excluding goodwill) | 64 | 18 | 19 | 0 | 0 | 0 | 0 | ||
| Restricted cash and investments | 2 | 2 | 2 | 2 | 2 | 1 | 1 | ||
| Other noncurrent assets | 7 | 8 | 5 | 3 | 3 | 3 | 3 | ||
| Total noncurrent assets: | 401 | 156 | 149 | 69 | 65 | 64 | 64 | ||
| TOTAL ASSETS: | 786 | 702 | 725 | 677 | 700 | 399 | 408 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 53 | 44 | 36 | 27 | 24 | 24 | 20 | ||
| Accounts payable | 23 | 15 | 11 | 9 | 9 | 5 | 6 | ||
| Accrued liabilities | 12 | 6 | 5 | 3 | 4 | 4 | 3 | ||
| Employee-related liabilities | 19 | 22 | 20 | 15 | 12 | 15 | 11 | ||
| Deferred revenue | 1 | ||||||||
| Debt | 2 | 2 | 3 | 3 | 3 | 3 | |||
| Other liabilities | 14 | 10 | 9 | 4 | 3 | 3 | 1 | ||
| Other undisclosed current liabilities | 13 | 8 | 8 | 6 | 6 | 6 | 7 | ||
| Total current liabilities: | 80 | 63 | 55 | 40 | 37 | 36 | 31 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 60 | 53 | 54 | 22 | 24 | 26 | 28 | ||
| Long-term debt, excluding current maturities | 1 | 1 | 2 | ||||||
| Operating lease, liability | 60 | 53 | 54 | 22 | 24 | 25 | 26 | ||
| Liabilities, other than long-term debt | 20 | 5 | 6 | 0 | 0 | 0 | |||
| Other liabilities | 20 | 5 | 6 | 0 | 0 | 0 | |||
| Other undisclosed noncurrent liabilities | (26) | ||||||||
| Total noncurrent liabilities: | 80 | 58 | 60 | 23 | 25 | 27 | 28 | ||
| Total liabilities: | 160 | 121 | 115 | 63 | 62 | 63 | 59 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 626 | 581 | 610 | 614 | 638 | 336 | 349 | ||
| Additional paid in capital | 1,282 | 1,191 | 1,179 | 1,143 | 1,129 | 795 | 783 | ||
| Accumulated other comprehensive income | 0 | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Accumulated deficit | (656) | (611) | (569) | (529) | (491) | (458) | (434) | ||
| Total stockholders' equity: | 626 | 581 | 610 | 614 | 638 | 336 | 349 | ||
| TOTAL LIABILITIES AND EQUITY: | 786 | 702 | 725 | 677 | 700 | 399 | 408 | ||
Income statement (P&L) ($ in millions)
| 12/31/2021 Q1 | 9/30/2021 Q4 | 6/30/2021 Q3 | 3/31/2021 Q2 | 12/31/2020 Q1 | 9/30/2020 Q4 | 6/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 42 | 38 | 35 | 31 | 28 | 32 | 21 | |
| Cost of revenue | (27) | (22) | (21) | (19) | (18) | (18) | (16) | |
| Gross profit: | 15 | 15 | 14 | 12 | 10 | 15 | 5 | |
| Operating expenses | (74) | (58) | (54) | (50) | (43) | (39) | (33) | |
| Other undisclosed operating income (loss) | 3 | 2 | (2) | |||||
| Operating loss: | (56) | (40) | (42) | (38) | (33) | (24) | (28) | |
| Nonoperating income (expense) | (0) | (1) | (0) | 0 | 0 | 0 | 0 | |
| Investment income, nonoperating | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other nonoperating income (expense) | (0) | (1) | (0) | 0 | (0) | (0) | (0) | |
| Interest and debt expense | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| Loss from continuing operations before income taxes: | (56) | (41) | (42) | (38) | (33) | (24) | (28) | |
| Income tax expense (benefit) | 10 | (0) | 2 | (0) | (0) | (0) | (0) | |
| Net loss available to common stockholders, diluted: | (46) | (41) | (40) | (38) | (33) | (24) | (28) | |
Comprehensive Income ($ in millions)
| 12/31/2021 Q1 | 9/30/2021 Q4 | 6/30/2021 Q3 | 3/31/2021 Q2 | 12/31/2020 Q1 | 9/30/2020 Q4 | 6/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (46) | (41) | (40) | (38) | (33) | (24) | (28) | |
| Other comprehensive income (loss) | (0) | 0 | 0 | 0 | 0 | (0) | (0) | |
| Comprehensive loss: | (46) | (41) | (40) | (38) | (33) | (24) | (28) | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 0 | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (45) | (41) | (40) | (38) | (33) | (24) | (28) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.